Introduction {#sec1-1}
============

Gastrointestinal (GI) subepithelial tumors (SETs) represent only a small proportion (\<1%) of all GI tumors and have a wide spectrum of presentations, pathologies, and prognosis \[[@ref1],[@ref2]\]. GI SETs include both non-neoplastic and neoplastic lesions. To delineate between high-risk lesions such as GI stromal tumors (GISTs) (which have a 30% potential for malignancy), and low-risk lesions such as lipomas, tests with high diagnostic yield and accuracy are essential \[[@ref1],[@ref3],[@ref4]\].

Standard endoscopy helps in the observational analysis of the size, margins, color and possible level of involvement within the wall of upper GI SETs \[[@ref5]\]. However, upper GI SETs are by definition below the mucosa; hence, for the purposes of preoperative diagnosis, invasive methods that include tissue sampling for cytology, histology and immunohistochemical analysis are often required \[[@ref5],[@ref6]\].

The current standard for obtaining tissue samples to differentiate between types of upper GI SETs is an endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). It has achieved gold standard status because of its diagnostic accuracy of 100% in lesions bigger than 40 mm. However, the accuracy of EUS-based approaches falls as lesions diminish in size, with accuracy falling to as low as 50% in lesions smaller than 20 mm \[[@ref7]\]. This variability in accuracy, along with other drawbacks, such as the cost of EUS-FNA, the average time it entails, and the required level of expertise required from an advanced endoscopist, has left the window open for improvements and alternative tissue sampling modalities \[[@ref8]\].

As the evolution of diagnostic methods for upper GI SETs continues, alternatives such as mucosal incision assisted biopsy (MIAB) have been developed, with a reported diagnostic yield of 89% \[[@ref8]\]. This technique was developed by Yokohata *et al* in 2007. In this method, saline is injected through the mucosa to create a submucosal fluid cushion in a manner similar to that used during saline-assisted polypectomy or endoscopic submucosal dissection. A needle knife or related device is then used to incise the mucosa and the submucosa until the GI SET is reached. Then, using cold forceps an average of 3-6 tissue samples are obtained \[[@ref8],[@ref9]\].

The duration of the procedure is similar to or less than the duration of an EUS-FNA. It is less expensive than an EUS-FNA, able to maneuver into locations that can be challenging with an EUS-FNA, and does not require advanced endoscopic training \[[@ref8]\]. No instances of perforation have been reported thus far \[[@ref5],[@ref8],[@ref10]-[@ref15]\]. Many are unaware of this technique or have not been exposed to it in a meaningful way. The aim of this systematic review and meta-analysis will be to analyze the overall diagnostic yield and complications of MIAB compared to the current standard of EUS/FNA.

Materials and methods {#sec1-2}
=====================

The objectives, primary and secondary outcomes, search strategy, inclusion and exclusion criteria, and methods for study selection, data extraction, and data synthesis of this meta-analysis were defined in a protocol in advance as per guidelines \[[@ref16],[@ref17]\].

Information sources and search strategy {#sec2-1}
---------------------------------------

A literature search was performed within the databases of PubMed, Cochrane Library and Web of Science. Various amalgamations of the following keywords were utilized: "mucosal incision assisted biopsy," "intraepithelial gastric lesions," "mucosal incision biopsy," "EUS-FNA," "GISTs," "stromal tumors," "upper gastrointestinal subepithelial tumors," "submucosal lesion," "EUS," and "EGD." Relevant studies chosen were published between August 2007 and August 2017.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

We followed the Preferred Reporting items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, using a predefined protocol to identify studies that reported the diagnostic yield of MIAB for upper GI SETs ([Fig. 1](#F1){ref-type="fig"}) \[[@ref18]\]. Study designs included comprised prospective and retrospective studies, as well as abstracts presented at national meetings. Studies with incomplete data and those not meeting the inclusion criteria were excluded.

![Study selection process in accordance with preferred reporting items for systematic reviews and meta-analysis statement (PRISMA)](AnnGastroenterol-33-155-g001){#F1}

Data extraction and quality assessment {#sec2-3}
--------------------------------------

Data were extracted and verified by independent reviewers. The initial screening stage consisted of searching for studies in which the title and abstract delineated evaluation of the diagnostic yield of MIAB of upper GI SETs in human subjects. In the subsequent stage, a complete examination of the article was undertaken to ensure its relevance to our points of interest. Data collected included the first author, year of publication, years the study spanned, type of study, total number of patients, size and type of upper GI SETs, and diagnostic yield of MIAB. We assessed the quality of included studies using a scale modified from the Newcastle---Ottawascalefor cohort studies \[[@ref18]\].

Outcomes assessed {#sec2-4}
-----------------

The primary outcome was the overall diagnostic yield of MIAB in the diagnosis of upper GI SETs. It was defined as the proportion of patients for whom the pathologist could provide a definitive diagnosis based on the specimen provided \[[@ref15]\].

The secondary outcome was to analyze adverse events, including but not limited to perforation and clinically significant bleeding. Clinically significant bleeding was defined as any bleeding requiring blood transfusion or endoscopic intervention \[[@ref5],[@ref15]\].

Statistical analysis {#sec2-5}
--------------------

We used meta-analysis techniques to calculate the pooled rates in each case, following the methods suggested by DerSimonian and Laird and using the random-effects model \[[@ref18]\]. All pooled rates were calculated with a 95% confidence interval (CI). A forest plot was constructed for the pooled estimates of both the primary outcome, diagnostic yield of MIAB, and the secondary outcomes. The variation of results across studies due to heterogeneity rather than chance was expressed by *I*^2^. *I*^2^ values of \<30%, 30-60%, 61-75% and \>75% were suggestive of low, moderate, substantial and considerable heterogeneity, respectively.

Results {#sec1-3}
=======

Literature search {#sec2-6}
-----------------

Using our search criteria, a total of 41 citations were identified. After duplicate studies were removed, 23 citations were reviewed. On final application of the inclusion and exclusion criteria, 7 studies that discussed the use of MIAB in the diagnosis of upper GI SETs were included. The meta-analysis thus included 7 independent cohort studies totaling 159 patients ([Fig. 1](#F1){ref-type="fig"}). All of them were single-center based. Three studies contained 27 or more patients, while 4 had between 12 and 15. Six studies were retrospective and one was prospective. Five studies were full publications and in original manuscript form. The remaining 2 studies were in abstract form and are still pending full publication. Of the 159 patients, 86 (54.1%) were male and 73 (45.9%) were female, with a mean age of 58 years. Study details are shown in [Table 1](#T1){ref-type="table"}.

###### 

Details of the studies included in our meta-analysis

![](AnnGastroenterol-33-155-g002)

Overall diagnostic yield {#sec2-7}
------------------------

In our study population, the overall pooled diagnostic yield of MIAB for upper GI SETs was 89% (95%CI 82.65-93.51, *I*^2^=0.00%), as outlined in the forest plot ([Fig. 2](#F2){ref-type="fig"}). GISTs were diagnosed in 38.62% of these (95%CI 22.29-56.24, *I*^2^=77.51%), followed by leiomyomas 25% (95%CI 18.02-32.62, *I*^2^=4.42%). The mean tumor size was 21.0 mm (95%CI 18.1-24.0, *I*^2^=89.73%). A majority of the upper GI SETs were located in the stomach (94.76%, 95%CI 78.46-100, *I*^2^=84.49%).

![Overall pooled diagnostic yield of mucosal incision assisted biopsy *ES, effect size; CI, confidence interval; N, number within sample size, p, probability value; I*^2^*, heterogeneity*](AnnGastroenterol-33-155-g003){#F2}

Adverse events {#sec2-8}
--------------

No perforations were not reported in any of the 7 studies. Overall, the rate of clinically significant bleeding following MIAB was 5.03% (95%CI 0.36-12.86, *I*^2^=57.43%), as outlined in the forest plot ([Fig. 3](#F3){ref-type="fig"}). A majority of bleeding events were immediate and controlled with endoscopic hemostatic measures.

![Rate of clinically significant bleeding following Mucosal incision assisted biopsy *ES, effect size; CI, confidence interval; N, number within sample size, p, probability value; I*^2^*, heterogeneity*](AnnGastroenterol-33-155-g004){#F3}

Validation of meta-analysis results {#sec2-9}
-----------------------------------

### Heterogeneity {#sec3-1}

Based on Q statistics and *I*^2^ analysis for heterogeneity, no heterogeneity was observed in the overall pooled diagnostic yield of MIAB for upper GI SETs. Within the category of upper GI SETs, considerable heterogeneity was noted in the diagnostic yield of GISTs (*I*^2^=77.51%), the mean tumor size (*I*^2^=89.73%), and the tumor location (*I*^2^=84.49%). Moderate heterogeneity (*I*^2^=57.43%) was noted in the rates of clinically significant bleeding.

### Publication bias and quality of the studies {#sec3-2}

The power to detect publication bias was low, given the small number of studies for comparison. The quality of the studies was assessed by the Newcastle---Ottawa scale ([Table 2](#T2){ref-type="table"}). Overall, 4 studies were considered to be of high quality and 3 studies were of low quality. None of the studies were of medium quality.

###### 

Newcastle--Ottawa scale for study quality assessment
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Discussion {#sec1-4}
==========

EUS-FNA is an established diagnostic modality for the investigation of upper GI SETs. It has attained this status because of its accuracy when dealing with large lesions and its minimal complication rate when performed by an experienced advanced endoscopist. Disadvantages of EUS-FNA include the diminishing diagnostic yield with smaller or difficult-to-reach GI SETs, the cost of the procedure, the need for it to be performed by a skilled advanced endoscopist, and the long procedure time. This systematic review of studies involving MIAB demonstrate this method's high diagnostic yield for upper GI SETs and its minimal complications, making it a viable alternative to EUS-FNA in the approach to upper GI SETs in centers that do not have an advanced endoscopist.

Our results showed a pooled diagnostic yield of 89% (95%CI 82.65-93.51, *I*^2^=0.00%) for upper GI SETs using the MIAB technique. In a study by Okuzono *et al*, the procedure took approximately 20 min, during which on average 6 biopsies were obtained \[[@ref8]\]. Ihara *et al* noted that MIAB only required an electrosurgical generator and electrosurgical knives, and the skills of a general gastroenterologist, whereas an EUS-FNA requires a linear echoendoscope, the skills of an advanced endoscopist, and, in some institutions, a cytotechnologist or cytologist for rapid onsite evaluation (ROSE) of the specimens, which can improve the diagnostic yield of an EUS-FNA sample by 24% on average \[[@ref11],[@ref12]\].

In our meta-analysis, MIAB had a bleeding rate of 5.03% (95%CI 0.36-12.86, *I*^2^=57.43%). One study reported a case of intraoperative bleeding that prevented the endoscopist from obtaining a sufficient number of tissue samples, while another reported delayed bleeding due to a deep biopsy \[[@ref8],[@ref10]\]. No perforations were reported in any of the 7 studies. Multiple studies noted that MIAB was a safe technique, with minimal bleeding and potentially a lower risk of complications when used on intraluminal versus extraluminal growths \[[@ref8],[@ref11],[@ref13]\].

Limitations of the included studies were that they were all single-center studies with small sample sizes (under 49 patients) and moderate-to-considerable heterogeneity.

Overall, MIAB is an effective and safe procedure for diagnosing GI SETs, with an overall diagnostic yield of 89% and a low rate of adverse events. This technique does not require advanced endoscopy training and can be performed by general gastroenterologists, potentially using fewer resources. Multi-center randomized control trials are needed to further validate these findings.

###### Summary Box

**What is already known:**

Endoscopic ultrasound-guided fine-needle aspiration and biopsy (EUS-FNA/EUS-FNB) is currently the gold standard for tissue diagnosis of upper gastrointestinal (GI) subepithelial tumors (SETs)EUS-FNA has a diagnostic accuracy of 100% in lesions larger than 40 mm; in lesions, between 20 mm and 40 mm its accuracy diminishes to 86-91%; and in lesions smaller than 20 mm it becomes \<50%This variability in accuracy and other drawbacks, such as the cost of EUS-FNA, the average time it entails, and the level of expertise required from an advanced endoscopist, have left the window open for improvements and alternative tissue sampling modalities

**What the new findings are:**

Mucosal incision-assisted biopsy is emerging as an alternative technique for the tissue diagnosis of upper GI SETs, with an overall diagnostic yield of 89%The duration of the procedure is similar to or less than the duration of an EUS-FNAIt is less expensive than an EUS-FNA, able to maneuver into locations that can be challenging with an EUS-FNA, and does not require advanced endoscopic trainingIt is an overall safer technique with minimal bleeding rates of 5% managed endoscopically, with no perforations have been noted
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